Stratos Wealth Partners LTD. trimmed its holdings in shares of The Clorox Company (NYSE:CLX – Free Report) by 1.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,654 shares of the company’s stock after selling 123 shares during the period. Stratos Wealth Partners LTD.’s holdings in Clorox were worth $1,370,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Dark Forest Capital Management LP acquired a new position in shares of Clorox during the 4th quarter valued at $28,000. OLD Mission Capital LLC acquired a new stake in Clorox in the fourth quarter valued at $29,000. Delta Asset Management LLC TN bought a new position in shares of Clorox during the fourth quarter worth about $31,000. Janiczek Wealth Management LLC lifted its stake in Clorox by 1,133.3% during the first quarter. Janiczek Wealth Management LLC now owns 222 shares of the company’s stock worth $35,000 after purchasing an additional 204 shares during the last quarter. Finally, Financial Avengers Inc. grew its position in shares of Clorox by 86.0% during the 4th quarter. Financial Avengers Inc. now owns 225 shares of the company’s stock valued at $32,000 after buying an additional 104 shares during the last quarter. 79.37% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on CLX. Wells Fargo & Company increased their target price on Clorox from $145.00 to $150.00 in a research report on Wednesday, May 3rd. StockNews.com started coverage on shares of Clorox in a research report on Thursday, May 18th. They issued a “hold” rating for the company. Bank of America lifted their price target on Clorox from $130.00 to $140.00 in a report on Wednesday, May 3rd. Royal Bank of Canada increased their price objective on Clorox from $137.00 to $151.00 in a report on Wednesday, May 3rd. Finally, UBS Group lifted their target price on Clorox from $148.00 to $162.00 in a research note on Wednesday, May 3rd. Seven research analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $148.54.
Clorox Price Performance
Clorox (NYSE:CLX – Get Free Report) last announced its earnings results on Tuesday, May 2nd. The company reported $1.51 EPS for the quarter, beating the consensus estimate of $1.22 by $0.29. The business had revenue of $1.92 billion during the quarter, compared to the consensus estimate of $1.82 billion. Clorox had a return on equity of 114.67% and a net margin of 1.03%. Clorox’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.31 earnings per share. As a group, equities analysts anticipate that The Clorox Company will post 4.56 EPS for the current fiscal year.
Clorox Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
Featured Stories
- Five stocks we like better than Clorox
- MarketBeat Week in Review – 7/10 – 7/14
- Wells Fargo’s Earnings, Why Markets Are Loving The Stock
- Citigroup Leads Banking Earnings, What’s Next?
- BlackRock Kicks Off Financials Earnings Season, Gauge To Markets
- JPMorgan Chase Is In Reversal But Don’t Chase It Higher
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX – Free Report).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.
